Identification and validation of heterotypic cell-in-cell structure as an adverse prognostic predictor for young patients of resectable pancreatic ductal adenocarcinoma
Identification and validation of heterotypic cell-in-cell structure as an adverse prognostic predictor for young patients of resectable pancreatic ductal adenocarcinoma
复制标题
DOI：
10.1038/s41392-020-00346-w
复制
发表时间：
2020
影响因子：
39.3
通讯作者：
Sun Qiang
中科院分区：
文献类型：
--
作者：
Huang Hongyan;He Meifang;Zhang Yanbin;Zhang Bo;Niu Zubiao;Zheng You;Li Wen;Cui Peilin;Wang Xiaoning;Sun Qiang
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with an overall 5-year survival rate of less than 10%. Between 20 and 30% of PDAC cases are resectable at diagnosis; however, patients' post-operative survival periods vary widely, irrespective of active therapeutic interventions. Therefore, extensive efforts have been made to identify biomarkers that may identify patients with an improved prognosis. Although profound local immune suppression had been implicated in PDAC progression and poor patient survival, a prognostic marker that can directly and functionally read immune evasion in situ is not yet available.
